Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP Inhibitors for Breast Cancer Treatment
Stefania Morganti, Antonio Marra, Carmine De Angelis, et al.
JAMA Oncology (2024) Vol. 10, Iss. 5, pp. 658-658
Closed Access | Times Cited: 22

Showing 22 citing articles:

DNA damage response in breast cancer and its significant role in guiding novel precise therapies
Jiayi Li, Ziqi Jia, Dong Lin, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
Aditi Jain, Alan Barge, Christopher N. Parris
Oncogene (2024)
Open Access | Times Cited: 6
From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment
Fatemah Basingab, Omniah A. Alshahrani, Ibtehal AlAnsari, et al.
Breast Cancer Targets and Therapy (2025) Vol. Volume 17, pp. 27-51
Open Access
A Rapid and Reliable Test for BRCA1 Promoter Hypermethylation in Paraffin Tissue Using Pyrosequencing
Ruben Bacares, Robert A. Soslow, Narciso Olvera, et al.
Diagnostics (2025) Vol. 15, Iss. 5, pp. 601-601
Open Access
Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review
Huan Jie, Wenhui Ma, Cong Huang
Breast Cancer Targets and Therapy (2025) Vol. Volume 17, pp. 265-274
Open Access
Germline variants analysis of Chinese breast cancer patients reveals numerous alterations in homologous recombination genes
Zhaoyun Jiang, Bing Xu, Bo Sun, et al.
Future Science OA (2025) Vol. 11, Iss. 1
Open Access
Targeting PCNA/PARP1 axis inhibits the malignant progression of hepatocellular carcinoma
LI Ji-pin, Yong Tao, Yali Chen, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Predictive biomarkers for immune checkpoint inhibitor (ICI) and poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) in advanced-stage breast carcinoma
Sarah Anderson, Brooke B. Bartow, Gene P. Siegal, et al.
Human Pathology Reports (2025) Vol. 40, pp. 300775-300775
Closed Access
Discovery of New Azaindole Metallo-Deubiquitinase CSN5 Inhibitors
Pengcheng Lei, Yu‐Hang Yan, Yingying Jiang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy
Kazuya Matsumoto, Yoshinori Matsumoto, Jun Wada
Frontiers in Immunology (2025) Vol. 16
Open Access
Leveraging Diverse Cell-Death Patterns to Decipher the Interactive Relation of Unfavorable Outcome and Tumor Microenvironment in Breast Cancer
Yue Li, Ting Ding, Tong Zhang, et al.
Bioengineering (2025) Vol. 12, Iss. 4, pp. 420-420
Open Access
Options for postoperative radiation therapy in patients with de novo metastatic breast cancer
Chaofan Li, Yusheng Wang, Binbin Fang, et al.
The Breast (2025), pp. 104483-104483
Open Access
Leveraging PARP-1/2 to Target Distant Metastasis
Mallory I. Frederick, Djihane Abdesselam, Anna Clouvel, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 9032-9032
Open Access | Times Cited: 2
Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial
Zahi Mitri, Allison Creason, Jayne M. Stommel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Nitro-fatty acids: promising agents for the development of new cancer therapeutics
Jessica Roos, Georg Manolikakes, Uwe Schlomann, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 11, pp. 1061-1080
Open Access | Times Cited: 2
Synthesis of novel deuterated EGFR/ALK dual-target inhibitors and their activity against non-small cell lung cancer
Haoran Nie, Shuai Zhang, Lihan Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117146-117146
Closed Access | Times Cited: 2
Mixtures of Three Mortaparibs with Enhanced Anticancer, Anti-Migration, and Antistress Activities: Molecular Characterization in p53-Null Cancer Cells
Renu Wadhwa, Shiming Yang, Hazna Noor Meidinna, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2239-2239
Open Access | Times Cited: 1
Advancements in Clinical Research and Emerging Therapies for Triple-Negative Breast Cancer Treatment
Lili Xu, Pengtao Xu, Jingsong Wang, et al.
European Journal of Pharmacology (2024), pp. 177202-177202
Closed Access | Times Cited: 1
Serum lipid ratios as novel prognostic biomarkers for patients with locally advanced breast cancer treated with neoadjuvant therapy
Xinru Chen, Yingying Zhao, Yaohui Wang, et al.
Postgraduate Medicine (2024) Vol. 136, Iss. 5, pp. 541-550
Closed Access
Medicaid Coverage of NCCN- and ASCO/SSO-Guideline-Concordant BRCA Germline Testing for Patients with Breast Cancer: Opportunity to Embrace Rapid Advancements in Precision Medicine
Hattie H Huston-Paterson, Vanessa Mora, Beth Y. Karlan, et al.
Annals of Surgical Oncology (2024)
Closed Access
Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer
S. Wu, Junnan Xu, Yiwen Ma, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
Hematopoietic adverse events associated with PARP inhibitors: A FAERS database study
Qindai Shuai, Xuefei Bai, Gen Li, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Closed Access
Page 1

Scroll to top